
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly reported a strong performance in the second quarter of 2025, exceeding expectations on both revenue and earnings, while also raising its full-year guidance. The company experienced a significant 60% quarter-over-quarter growth in international sales of Mounjaro, enhanced by successful launches in new markets such as Brazil, Mexico, and India. This robust sales momentum, particularly in key product lines, underscores Eli Lilly's solid market position and potential for continued financial growth.
Bears say
Eli Lilly has experienced a notable decline in the prescription volume of Zepbound in July, which is anticipated to adversely affect volumetric growth in the third quarter. The company faces several downside risks, including potential pricing pressures and an unfavorable trajectory for tirzepatide (Mounjaro), especially concerning its efficacy in demonstrating cardiac outcomes in both diabetic and non-diabetic obese patients. Additionally, heightened competition from drugs like orforglipron and a downward revision of its peak sales forecasts further contribute to a challenging outlook for the firm.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares